| Co-efficient | 95% CI | |||
|---|---|---|---|---|
| Lower | Upper | |||
| 2015–2016 QP in bottom 80% of prescribers | -0.116 | -0.125 | -0.106 | |
| Effect of 2015–2016 QP in top 20% of prescribers | -0.200 | -0.210 | -0.187 | |
| Top 20% of prescribers | 0.309 | 0.302 | 0.316 | |
| Months since QP | 0.013 | 0.013 | 0.014 | |
| Season | Winter | Ref | Ref | Ref |
| Spring | -0.046 | -0.049 | -0.044 | |
| Summer | -0.148 | -0.151 | -0.145 | |
| Autumn | -0.124 | -0.126 | -0.121 | |
| Comorbidities prevalence per 100 patients | Respiratory diseases | 0.013 | 0.011 | 0.015 |
| Diabetes (<3.93%) | 0.097 | 0.089 | 0.106 | |
| Diabetes (≥3.93% to ≤7.59%) | 0.015 | 0.012 | 0.017 | |
| Diabetes (≥7.60% to ≤11.28%) before QP | 0.016 | 0.012 | 0.021 | |
| Diabetes (≥7.60% to ≤11.28%) after QP | 0.007 | 0.002 | 0.011 | |
| Diabetes (>11.28%) | 0.041 | 0.030 | 0.052 | |
| GPHC per 10 000 patients, spline terms | GPHC1 (<4.91) before QP | 0.015 | 0.013 | 0.017 |
| GPHC1 (<4.91) after QP | 0.007 | 0.005 | 0.009 | |
| GPHC2 (≥4.91 to ≤9.80) before QP | -0.007 | -0.009 | -0.005 | |
| GPHC2 (≥4.91 to ≤9.80) after QP | -0.005 | -0.007 | -0.003 | |
| GPHC3 (≥9.81 to ≤14.72) | 0.005 | -0.000 | 0.010 | |
| GPHC4 (>14.72) | -0.007 | -0.022 | 0.008 | |
| Benzodiazepine anxiolytics prescription | 0.093 | 0.089 | 0.097 | |
| Benzodiazepine hypnotics prescription | 0.118 | 0.115 | 0.121 | |
Effects of diabetes are per 1% higher within each spline term. Effects of GPHC are per 1 higher per 10 000 patients within each spline term. GPHC = GP headcount. QP = Quality Premium.